Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
暂无分享,去创建一个
William Smith | E. Wajs | T. Marbury | N. Vaccaro | H. Stieltjes | D. Devineni | C. Curtin | A. Vandebosch | D. Wexler | Sarah Rusch